Blauwendraat, Cornelis

The genetic architecture of Parkinson's disease

Blauwendraat, C., Nalls, M. A., & Singleton, A. B. (2020) · The Lancet Neurology

Parkinson's Disease Mechanisms and TreatmentsGenetic Associations and Epidemiology

Cited by 1,114

Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture

Chia, R., Sabir, M. S., Bandres-Ciga, S., Saez-Atienzar, S., Reynolds, R. H., Gustavsson, E., Walton, R. L., Ahmed, S., Viollet, C., Ding, J., et al. (2021) · Nature Genetics

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 438

Genome-wide pleiotropy between Parkinson disease and autoimmune diseases

Witoelar, A., Jansen, I. E., Wang, Y., Desikan, R. S., Gibbs, J. R., Blauwendraat, C., Thompson, W. K., Hernandez, D. G., Djurovic, S., Schork, A. J., et al. (2017) · JAMA Neurology

Parkinson's Disease Mechanisms and TreatmentsGenetic Associations and Epidemiology

Cited by 352

Virus exposure and neurodegenerative disease risk across national biobanks

Levine, K. S., Leonard, H. L., Blauwendraat, C., Iwaki, H., Johnson, N., Bandres-Ciga, S., Ferrucci, L., Faghri, F., Singleton, A. B., & Nalls, M. A. (2023) · Neuron

Multiple Sclerosis Research StudiesDementia and Cognitive Impairment Research

Cited by 341

A reference human induced pluripotent stem cell line for large-scale collaborative studies

Pantazis, C. B., Yang, A., Lara, E., McDonough, J. A., Blauwendraat, C., Peng, L., Oguro, H., Kanaujiya, J., Zou, J., Sebesta, D., et al. (2022) · Cell Stem Cell

Pluripotent Stem Cells ResearchCRISPR and Genetic Engineering

Cited by 310

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

DESGESCO (Dementia Genetics Spanish Consortium), E. (. D. E. D. B., van der Lee, S. J., biobank), E. (. D. E. D., IFGC (International FTD-Genomics Consortium), I. (. I. P. D. G. C., IPDGC (The International Parkinson Disease Genomics Consortium), Dementia), R.-F. (. A. M. F. I. F.-T., (NBB), N. B. B., The GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Conway, O. J., Jansen, I., et al. (2019) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 120

Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study

Jabbari, E., Koga, S., Valentino, R. R., Reynolds, R. H., Ferrari, R., Tan, M. M. X., Rowe, J. B., Dalgard, C. L., Scholz, S. W., Dickson, D. W., et al. (2021) · The Lancet Neurology

Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Cited by 111

Parkinson’s disease variant detection and disclosure: PD GENEration, a North American study

Cook, L., Verbrugge, J., Schwantes-An, T.-H., Schulze, J., Foroud, T., Hall, A., Marder, K. S., Mata, I. F., Mencacci, N. E., Nance, M. A., et al. (2024) · Brain

Parkinson's Disease Mechanisms and TreatmentsGenomics and Rare Diseases

Cited by 108

Association of a common genetic variant with Parkinson’s disease is mediated by microglia

Langston, R. G., Beilina, A., Reed, X., Kaganovich, A., Singleton, A. B., Blauwendraat, C., Gibbs, J. R., & Cookson, M. R. (2022) · Science Translational Medicine

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 93

The Parkinson's Disease Genome‐Wide Association Study Locus Browser

Grenn, F. P., Kim, J. J., Makarious, M. B., Iwaki, H., Illarionova, A., Brolin, K., Kluss, J. H., Schumacher‐Schuh, A. F., Leonard, H., Faghri, F., et al. (2020) · Movement Disorders

Parkinson's Disease Mechanisms and TreatmentsGenetic Associations and Epidemiology

Cited by 92

Lower Lymphocyte Count is Associated With Increased Risk of Parkinson's Disease

Jensen, M. P., Jacobs, B. M., Dobson, R., Bandres‐Ciga, S., Blauwendraat, C., Schrag, A., Noyce, A. J., & The International Parkinson's Disease Genomics Consortium (IPDGC) (2021) · Annals of Neurology

Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 91

The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease

Bandres‐Ciga, S., Saez‐Atienzar, S., Bonet‐Ponce, L., Billingsley, K., Vitale, D., Blauwendraat, C., Gibbs, J. R., Pihlstrøm, L., Gan‐Or, Z., The International Parkinson's Disease Genomics Consortium (IPDGC), et al. (2019) · Movement Disorders

Parkinson's Disease Mechanisms and TreatmentsGenetic Associations and Epidemiology

Cited by 90

GALC variants affect galactosylceramidase enzymatic activity and risk of Parkinson’s disease

Senkevich, K., Zorca, C. E., Dworkind, A., Rudakou, U., Somerville, E., Yu, E., Ermolaev, A., Nikanorova, D., Ahmad, J., Ruskey, J. A., et al. (2023) · Brain

Lysosomal Storage Disorders ResearchParkinson's Disease Mechanisms and Treatments

Cited by 40

The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1

Gustavsson, E. K., Sethi, S., Gao, Y., Brenton, J. W., García-Ruiz, S., Zhang, D., Garza, R., Reynolds, R. H., Evans, J. R., Chen, Z., et al. (2024) · Science Advances

Lysosomal Storage Disorders ResearchGenomics and Phylogenetic Studies

Cited by 30

Assessment of APOE in atypical parkinsonism syndromes

Sabir, M. S., Blauwendraat, C., Ahmed, S., Serrano, G. E., Beach, T. G., Perkins, M., Rice, A. C., Masliah, E., Morris, C. M., Pihlstrom, L., et al. (2019) · Neurobiology of Disease

Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Cited by 28

Genome-wide determinants of mortality and motor progression in Parkinson’s disease

Tan, M. M. X., Lawton, M. A., Pollard, M. I., Brown, E., Real, R., Carrasco, A. M., Bekadar, S., Jabbari, E., Reynolds, R. H., Iwaki, H., et al. (2024) · npj Parkinson's Disease

Parkinson's Disease Mechanisms and TreatmentsGenetic Associations and Epidemiology

Cited by 17